Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
7.99
-0.04 (-0.50%)
At close: Nov 2, 2026, 4:00 PM EST
8.02
+0.03 (0.38%)
After-hours: Nov 2, 2026, 4:10 PM EST

Xilio Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5334421574437
Market Cap Growth
25.23%-19.94%177.26%-79.46%-83.14%-
Enterprise Value
-77-63-11-30-45581
Last Close Price
8.038.9613.377.7037.66224.00

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.800.776.62---
PB Ratio
0.730.952.380.410.702.36
P/TBV Ratio
0.710.952.380.410.702.36

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.090.200.460.340.190.11
Net Debt / Equity Ratio
-1.79-3.70-2.68-0.87-0.95-0.96
Net Debt / EBITDA Ratio
4.323.230.810.421.152.41
Net Debt / FCF Ratio
2.1223.702.560.471.292.17
Asset Turnover
0.450.390.10---
Quick Ratio
4.152.532.032.805.7015.50
Current Ratio
4.252.582.213.025.9015.85
Return on Equity (ROE)
-55.03%-132.53%-214.02%-107.25%-60.62%-84.16%
Return on Assets (ROA)
-13.61%-23.24%-56.48%-49.44%-31.20%-36.88%
Return on Capital Employed (ROCE)
-26.10%-42.70%-136.10%-176.00%-75.50%-36.60%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-41.52%-104.24%-138.74%-504.62%-119.66%-17.33%
FCF Yield
-119.07%-16.39%-43.86%-456.42%-105.24%-18.72%
Buyback Yield / Dilution
-77.75%-18.53%-94.61%-0.38%-388.59%-970.35%
SEC Filings: 10-K · 10-Q